[1] ZHANG Y, CHEN L, HU GQ, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma[J]. N Engl J Med, 2019, 381(12): 1124. doi: 10.1056/NEJMoa1905287
[2] MAO YP, XIE FY, LIU LZ, et al. Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging[J]. Int J Radiat Oncol Biol Phys, 2009, 73(5): 1326. doi: 10.1016/j.ijrobp.2008.07.062
[3] ZHANG L, HUANG Y, HONG S, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial[J]. Lancet, 2016, 388(10054): 1883. doi: 10.1016/S0140-6736(16)31388-5
[4] SUN Y, LI WF, CHEN NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregion-ally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial[J]. Lancet Oncol, 2016, 17: 1509. doi: 10.1016/S1470-2045(16)30410-7
[5] LIN S, PAN J, HAN L, et al. Update report of nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy and hypothesis of the optimal margin[J]. Radiother Oncol, 2014, 110(3): 385. doi: 10.1016/j.radonc.2014.01.011
[6] LEE AW, NG WT, CHAN LL, et al. Evolution of treatment for nasopharyngeal cancer success and setback in the intensity-modulated radiotherapy era[J]. Radiother Oncol, 2014, 110(3): 377. doi: 10.1016/j.radonc.2014.02.003
[7] LU SH, CHENG CH, KUO SH, et al. volumetric modulated arc therapy for nasopharyngeal carcinoma: a dosimetric comparison with TomoTherapy and step-and shoot IMRT[J]. Radiother Oncol, 2012, 104(3): 324. doi: 10.1016/j.radonc.2011.11.017
[8] DU L, ZHANG XX, MA L, et al. Clinical study of nasopharyngeal carcinoma treated by helical tomotherapy in China: 5-year outcomes[J]. Biomed Res Int, 2014, 2014: 980767.
[9] HERRMANN T, KNORR A, DRNER K. The RTOG/EORTC classification criteria for early and late radiation reactions[J]. Radiobiol Radiother(Berl), 1987, 28(4): 519.
[10] EISENHAUER EA, THERASSE P, BOGAERTS J, et al. New response evaluation criteriain solid tumours: revised RECIST guideline(version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228. doi: 10.1016/j.ejca.2008.10.026
[11] PUEBLA F, LOPEZ GUERRA JL, GARCIA RAMIREZ JM, et al. Effectiveness and toxicity of helical tomotherapy for patients with locally recurrent nasopharyngeal carcinoma[J]. Clin Transl Oncol, 2015, 17(11): 925. doi: 10.1007/s12094-015-1328-5
[12] ZHANG X, DU L, ZHAO FF, et al. A phase Ⅱ clinical trial of concurrent helical tomotherapy plus cetuximab filllowed by adjuvant chemotherapy with cisplatin and docetaxel for locally advanced nasopharyngeal eareiuolna[J]. Int J Biol Sci, 2016, 12(4): 446. doi: 10.7150/ijbs.12937
[13] 周闪, 钱建军, 徐亮, 等. 涎腺早期放射性损伤的磁共振定量评价[J]. 中华医学杂志, 2017, 97(7): 492. doi: 10.3760/cma.j.issn.0376-2491.2017.07.004
[14] LU SH, CHENG JC, KUO SH, et al. Volumetric modulated arc therapy for nasopharyngeal carcinoma: a dosimetric comparison with Tomo Therapy and step-and-shoot IMRT[J]. Radiother Oncol, 2012, 104(3): 324. doi: 10.1016/j.radonc.2011.11.017
[15] SERVAGI VERNAT S, ALI D, PUYRAVEAU M, et al. Is IMAT the ultimate evolution of conformal radiotherapy? Dosimetric comparison of helical tomotherapy and volumetric modulated arc therapy for oropharyngeal cancer in a planning study[J]. Phys Med, 2014, 30(3): 280. doi: 10.1016/j.ejmp.2013.07.128
[16] LEUNG SW, LEE TF. Treatment of nasopharyngeal carcinoma bytomotherapy: five-year experience[J]. Radiat Oncol, 2013, 8(1): 107. doi: 10.1186/1748-717X-8-107
[17] LU J, MA YD, CHEN JH, et al. Assessment of anatomical and Dosimetric changes by a deformable registration method during the course of intensity-modulated radiotherapy for nasopharyngeal carcinoma[J]. J Radiat Res, 2014, 55(1): 97. doi: 10.1093/jrr/rrt076
[18] DUMA M N, KAMPFER S, WILKENS JJ, et al. Comparative analysis of an image-guided versus a non-image-guided setup approach in terms of delivered dose to the parotid glands in head-and-neck cancer IMRT[J]. Int J Radiat Oncol Biol Phys, 2010, 77(4): 1266. doi: 10.1016/j.ijrobp.2009.09.047
[19] BHANDARE N, JACKSON A, EISBRUEH A, et al. Radiation therapy and hearing loss[J]. Int J Radiat Oncol Biol Phys, 2010, 76(3): 50. doi: 10.1016/j.ijrobp.2009.04.096
[20] 卢丽娜, 钱建军, 宦坚, 等. 鼻咽癌IMRT中耳蜗限量和内耳整体限量方法对内耳结构保护差异的研究[J]. 中华放射肿瘤学杂志, 2017, 26(9): 997. doi: 10.3760/cma.j.issn.1004-4221.2017.09.004
[21] LI JX, ZHAO ZF, WU X, et al. Bevacizumab plus cisplatin and helical tomotherapy in treatment of locally advanced nasopharyngeal carcinoma[J]. Onco Targets Ther, 2015(8): 1315.